A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

PHASE3CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

October 4, 2012

Primary Completion Date

October 8, 2014

Study Completion Date

October 8, 2014

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Solifenacin succinate suspension

Oral suspension

Trial Locations (39)

1108

Site: 6301, Quezon City

2020

Site: 3202, Antwerp

2650

Site: 3209, Antwerp

3000

Site: 3205, Leuven

4530

Site: 5202, Mexico City

4600

Site: 4504, Køge

5021

Site: 4701, Bergen

6000

Site: 3208, Charleroi

Site: 4502, Kolding

6100

Site: 9001, Ankara

7700

Site: 2703, Cape Town

8200

Site: 4501, Aarhus N

8500

Site: 3204, Kortrijk

9000

Site: 3201, Ghent

Site: 3203, Ghent

11883

Site: 4602, Stockholm

21000

Site: 3812, Novi Sad

35100

Site: 9002, Izmir

41685

Site: 4606, Gothenburg

54185

Site: 4603, Skövde

71106

Site: 1006, Shreveport

90185

Site: 4605, Umeå

110744

Site: 8207, Seoul

156707

Site: 8202, Seoul

705717

Site: 8203, Daegu

13087-567

Site: 5507, Campinas

80240-060

Site: 5506, Curitiba

G1V 4G2

Site: 1001, Québec

DK-9000

Site: 4503, Aalborg

C.P.06700

Site: 5205, Mexico City

80-803

Site: 4805, Gdansk

80-952

Site: 4803, Gdansk

20-093

Site: 4804, Lubin

04-736

Site: 4801, Warsaw

11 000

Site: 3810, Belgrade

400-711

Site: 8206, Incheon

Unknown

Site: 3854, Kharkiv

LS1 3EX

Site: 4403, Leeds

S10 2TH

Site: 4401, Sheffield

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT01655069 - A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 | Biotech Hunter | Biotech Hunter